STOCK TITAN

Annovis Bio, Inc. - ANVS STOCK NEWS

Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.

Annovis Bio, Inc. (NYSE: ANVS) is a clinical-stage pharmaceutical company dedicated to developing novel therapies for neurodegenerative diseases such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD). Headquartered in Malvern, Pennsylvania, Annovis is pioneering innovative approaches to combat neurodegeneration by targeting multiple neurotoxic proteins simultaneously. The company’s lead compound, Buntanetap (formerly Posiphen or ANVS401), is designed to inhibit the formation of amyloid beta, tau, alpha-synuclein, and TDP43, aiming to improve synaptic transmission and axonal transport while reducing neuroinflammation.

Annovis Bio’s flagship product, Buntanetap, is in phase II/III clinical trials for the treatment of mild to moderate AD and early PD. The drug has shown promising results, demonstrating significant improvements in cognitive function and reducing neurotoxic biomarkers in patients. Alongside Buntanetap, the company is advancing ANVS405 for acute neurodegeneration post-traumatic brain injury and stroke, and ANVS301, currently in phase I trials, aimed at enhancing cognitive capabilities in advanced AD and dementia.

Founded in 2008 by Dr. Maria Maccecchini, Ph.D., Annovis Bio continues to focus on restoring brain function to alleviate symptoms and improve the quality of life for individuals affected by neurodegenerative diseases. The company has established itself as a leader in the field through partnerships, rigorous scientific research, and a commitment to transparency with all stakeholders.

Recent achievements include the completion of a Phase II/III study of Buntanetap in Alzheimer’s patients, demonstrating a statistically significant improvement in cognition and a favorable safety profile. Additionally, Annovis has filed a patent application for the use of Buntanetap in treating neuropsychiatric conditions such as autism and bipolar disorder, highlighting the drug’s versatile potential.

A financial overview reveals that Annovis ended the first quarter of 2024 with $3.1 million in cash, ensuring operational sustainability into the fourth quarter through strategic financial management. The company has actively engaged with the scientific and investment communities, participating in notable conferences like the International Conference on Alzheimer’s and Parkinson’s Diseases and hosting investor calls to discuss clinical milestones and future plans.

For more information about Annovis Bio, visit their website and follow them on LinkedIn and X (formerly Twitter).

Rhea-AI Summary

Annovis Bio Inc. (NYSE American: ANVS) announced that its Founder and CEO, Maria Maccecchini, Ph.D., will receive the 2020 Smart Business Dealmaker Award at the Smart Business Dealmakers Conference on October 22. Dr. Maccecchini expressed gratitude for the recognition and highlighted the team's efforts that contributed to the company’s successful IPO earlier this year. Annovis Bio is focused on treating neurodegenerative diseases, including Alzheimer's and Parkinson's, and is currently conducting Phase 2a studies on its treatments. The award ceremony runs from 12:30 PM to 1:00 PM ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.04%
Tags
none
-
Rhea-AI Summary

On October 20, 2020, Annovis Bio (NYSE American: ANVS) announced participation by CEO Maria Maccecchini, Ph.D., in the Financial Times' Outstanding Director Exchange (ODX) Roundtable, discussing the evolving relationship between pharma and biotech. She will also join the Angel Venture Fair Women’s Founders and Funders panel. With extensive experience since 1992, Dr. Maccecchini aims to share insights beneficial to directors and aspiring women entrepreneurs. Annovis specializes in treatments for Alzheimer’s and Parkinson’s diseases, with ongoing clinical studies aimed at improving cognitive and motor functions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
Rhea-AI Summary

On October 15, 2020, Annovis Bio Inc. (ANVS) reported significant advancements in its business operations for Q3 2020. The company announced the initiation of a Phase 2a clinical study for its lead compound, ANVS401, targeting Alzheimer’s and Parkinson’s diseases, with preliminary data expected in early 2021. Annovis Bio also restarted a previously halted Alzheimer's study, completed a chronic toxicology study with favorable safety results, and published three scientific papers corroborating its findings. Additionally, the company secured two patents and filed five more related to treatments for neurodegenerative diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

On October 12, 2020, Annovis Bio (NYSE American: ANVS) announced that its CEO, Maria Maccecchini, will present at the 2020 BIO Investor Forum, taking place October 13-15, 2020, in a digital format. The presentation will be available on demand for registered attendees. Annovis Bio focuses on developing treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD), and Alzheimer’s in Down Syndrome (AD-DS), targeting neurotoxic proteins to enhance nerve cell function. For further information, visit www.annovisbio.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
conferences
-
Rhea-AI Summary

On September 3, 2020, Annovis Bio Inc. (NYSE American: ANVS) announced a televised interview with CEO Maria Maccecchini, airing on The RedChip Money Report on September 6 at 6 p.m. local time. The interview will discuss the Company's innovative approach to treating neurodegenerative diseases, including ongoing Phase 2a studies in Alzheimer’s and Parkinson’s diseases. Additionally, viewers can catch the program in the U.S. on the Action Channel. Annovis focuses on multi-target solutions for neurodegeneration, aiming to improve conditions like memory loss associated with Alzheimer's.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
none
-
Rhea-AI Summary

On September 1, 2020, Annovis Bio Inc. (ANVS) announced the dosing of the first three patients in its Phase 2a clinical trial for Alzheimer’s disease (AD) and Parkinson’s disease (PD). The trial, which has IRB approval, will enroll a total of 28 patients over four weeks, focusing on the drug ANVS401's ability to reverse toxic nerve cell death. Initial data is expected in early 2021, followed by a larger dose-response trial. This is a significant milestone for the company, which aims to offer a novel treatment for these neurodegenerative diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.47%
Tags
Rhea-AI Summary

Annovis Bio Inc. (NYSE American:ANVS) announced its participation in the LD 500 investor conference on September 1, 2020, at 9:20 AM EDT. CEO Maria Maccecchini will present the company’s innovative approach to treating Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. The company is currently conducting two Phase 2 trials focused on these conditions. The LD 500, running from September 1-4, will be virtual, making it accessible to all interested parties. For more information, visit annovisbio.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
conferences
-
Rhea-AI Summary

Annovis Bio Inc. (NYSE American: ANVS) has resumed patient recruitment for its suspended Phase 2a clinical trial targeting Alzheimer’s disease (AD) and initiated a new Phase 2a trial for both AD and Parkinson’s disease (PD). The first trial involves 24 patients and is in collaboration with major institutions. Initial data is expected in early 2021. The second trial will also enroll patients across 15 US sites, with results anticipated in summer 2021. The company plans to report final data from long-term toxicology studies by fall 2020 to confirm the safety of its lead compound, ANVS401.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
-
Rhea-AI Summary

On July 23, 2020, Annovis Bio (NYSE American: ANVS) announced that CEO Maria Maccecchini will appear on Executive Leaders Radio on July 26, 2020. The show focuses on interviews with prominent CEOs, particularly within life sciences, discussing professional success and personal stories. Dr. Maccecchini expressed her enthusiasm for sharing the Annovis story and her personal commitment to neurodegeneration solutions. Annovis Bio, based in Berwyn, PA, is focused on developing drugs for Alzheimer’s and Parkinson’s diseases, with ongoing Phase 2a studies targeting these conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.23%
Tags
none
Rhea-AI Summary

Annovis Bio (NYSE American: ANVS) announces that CEO Maria Maccecchini, Ph.D., will present at the University of Pennsylvania on July 20, 2020. Her talk, titled “Rethinking Parkinson’s Disease”, addresses a novel treatment approach for Parkinson's disease at the Parkinson’s Disease and Movement Disorders Center, recognized as a global Center of Excellence.

Maccecchini will discuss the toxic cascade caused by neurotoxic proteins in neurodegenerative diseases, presenting data from clinical trials using ANVS401, Annovis Bio's lead compound.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.65%
Tags
conferences

FAQ

What is the current stock price of Annovis Bio (ANVS)?

The current stock price of Annovis Bio (ANVS) is $5.01 as of December 24, 2024.

What is the market cap of Annovis Bio (ANVS)?

The market cap of Annovis Bio (ANVS) is approximately 69.1M.

What is Annovis Bio, Inc.?

Annovis Bio, Inc. is a clinical-stage pharmaceutical company focused on developing drugs to treat neurodegenerative diseases such as Alzheimer's and Parkinson's.

What is Buntanetap?

Buntanetap is Annovis Bio's leading drug candidate designed to inhibit multiple neurotoxic proteins, aiming to improve cognitive function in patients with neurodegenerative diseases.

Where is Annovis Bio headquartered?

Annovis Bio is headquartered in Malvern, Pennsylvania.

Who founded Annovis Bio?

Annovis Bio was founded by Dr. Maria Maccecchini, Ph.D., in 2008.

What are the key focus areas for Annovis Bio?

Annovis Bio focuses on developing drugs for Alzheimer’s Disease, Parkinson’s Disease, traumatic brain injury, stroke, and other neurodegenerative conditions.

What recent achievements has Annovis Bio accomplished?

Recent achievements include the completion of a Phase II/III study of Buntanetap in Alzheimer’s patients and the filing of a patent application for its use in treating neuropsychiatric conditions.

What are the financial highlights for Annovis Bio?

As of the first quarter of 2024, Annovis Bio reported $3.1 million in cash and continues to effectively manage its financial resources.

What is ANVS405?

ANVS405 is a drug in development by Annovis Bio for protecting the brain after traumatic brain injury and stroke.

What is ANVS301?

ANVS301 is an Annovis Bio drug in phase I clinical trials aimed at increasing cognitive capability in advanced stages of Alzheimer's Disease and dementia.

How can I learn more about Annovis Bio's developments?

For more information, visit Annovis Bio's official website at www.annovisbio.com and follow them on LinkedIn and X (formerly known as Twitter).

Annovis Bio, Inc.

NYSE:ANVS

ANVS Rankings

ANVS Stock Data

69.12M
10.98M
20.4%
8.83%
10.1%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MALVERN